- Home
- SPKL vs MDWD Comparison
SPKL vs MDWD Comparison
Compare SPKL & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- MDWD
- Stock Information
- Founded
- SPKL 2021
- MDWD 2000
- Country
- SPKL United States
- MDWD Israel
- Employees
- SPKL N/A
- MDWD N/A
- Industry
- SPKL
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- SPKL
- MDWD Health Care
- Exchange
- SPKL Nasdaq
- MDWD Nasdaq
- Market Cap
- SPKL 170.5M
- MDWD 179.1M
- IPO Year
- SPKL 2023
- MDWD 2014
- Fundamental
- Price
- SPKL $10.47
- MDWD $17.18
- Analyst Decision
- SPKL
- MDWD Strong Buy
- Analyst Count
- SPKL 0
- MDWD 1
- Target Price
- SPKL N/A
- MDWD $28.00
- AVG Volume (30 Days)
- SPKL 25.9K
- MDWD 63.5K
- Earning Date
- SPKL 01-01-0001
- MDWD 08-14-2024
- Dividend Yield
- SPKL N/A
- MDWD N/A
- EPS Growth
- SPKL N/A
- MDWD N/A
- EPS
- SPKL 0.12
- MDWD N/A
- Revenue
- SPKL N/A
- MDWD $20,141,000.00
- Revenue This Year
- SPKL N/A
- MDWD $30.16
- Revenue Next Year
- SPKL N/A
- MDWD $18.44
- P/E Ratio
- SPKL $85.74
- MDWD N/A
- Revenue Growth
- SPKL N/A
- MDWD N/A
- 52 Week Low
- SPKL $10.07
- MDWD $7.45
- 52 Week High
- SPKL $11.35
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- SPKL 63.26
- MDWD 43.87
- Support Level
- SPKL $10.45
- MDWD $16.25
- Resistance Level
- SPKL $10.46
- MDWD $17.48
- Average True Range (ATR)
- SPKL 0.01
- MDWD 0.97
- MACD
- SPKL -0.00
- MDWD -0.19
- Stochastic Oscillator
- SPKL 41.67
- MDWD 18.60
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.